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Article: Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic 
non-specific diarrhea
(J Neurogastroenterol Motil 2010;16:40-46)
Small intestinal bacterial overgrowth (SIBO) is a clinical 
condition caused by excessive number of bacteria in the small 
bowel. SIBO is characterized by symptoms of diarrhea, abdomi-
nal pain, or bloating which may be associated with excessive gas 
of small intestine due to increased production by bacterial fer-
mentation in the gut. In the last decade, SIBO has been occupied 
as a hot topic of interests by a group of researchers because of its 
potential role in the development of irritable bowel syndrome 
(IBS).1 
In the diagnosis of SIBO, a bacterial count greater than 105 
colony-forming units/mL by small bowel culture is believed to be 
the gold standard.2 But small bowel culture through jejunal aspi-
rate is time-consuming, invasive, and potential for contamination. 
Due to several flaws of small bowel culture, a number of non-
invasive and indirect tests for diagnosing SIBO have been 
developed. Breath test, the most common indirect method for 
evaluating SIBO, utilizes the metabolism of carbohydrates by 
bacterial enzymes, in turn indirectly measures bacterial activity of 
small bowel. Different carbohydrates have different properties. 
As lactulose is a non-absorbable carbohydrate, it easily reaches 
the site of potential overgrowth in the small bowel, although non-
absorbed carbohydrate has limitations by the intestinal transit 
time. In patients with rapid transit, lactulose may produce an ear-
ly hydrogen peak which makes it difficult to discriminate the true 
SIBO from a phenomenon by rapid intestinal transit, therefore 
specificity of lactulose hydrogen breath test (LHBT) is relatively 
low.3 
Pimentel and colleagues4 suggested a concept that SIBO is a 
major pathogenic mechanism underlying IBS in 2000. They have 
found 78% of 202 IBS subjects to be positive for LHBT which is 
suggestive of SIBO. They also demonstrated a significant im-
provement in symptoms including abdominal pain, bloating, and 
diarrhea by treating SIBO with antibiotics and converted many 
IBS patients from Rome criteria positive to negative. 
Since then, SIBO has been proposed as an etiologic factor in 
IBS, but also the potential role of SIBO in IBS has been strongly 
debated about the methods used in diagnosing SIBO. A 
prevalence of SIBO in subjects meeting diagnostic criteria for 
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IBS varies from 4% to 64%, depending on the kind of test and 
criteria used to define a positive result.5 In addition, a recent 
well-designed study from the US6 using LHBT to diagnose 
SIBO could not discriminate patients with IBS from healthy 
subjects, which was a consistent finding the authors de-
monstrated previously.7 Therefore, the proposed etiologic role of 
SIBO diagnosed by LHBT in IBS patients is controversial and 
the correlation between the normalization of the LHBT 
following antibiotic treatment and symptom improvement has 
become less clear.  
Glucose, on the other hand, is rapidly absorbed in the prox-
imal small bowel. Thereby detecting hydrogen in this test means 
SIBO in a proximal location. Glucose hydrogen breath test 
(GHBT) is the most commonly used test in the diagnosis of 
SIBO, although GHBT may be less sensitive for the diagnosis of 
SIBO since it is absorbed in the proximal small bowel. GHBT 
has been reported to have a overall sensitivity between 25% to 
93% and a specificity from 34% to 96% in detecting SIBO.3,5  
In this issue of the Journal of Neurogastroenterology and 
Motility, Ghoshal et al. reported the frequency of SIBO in pa-
tients with IBS and chronic non-specific diarrhea (CNSD) with 
comparison to healthy controls by using GHBT. The authors 
found that SIBO was more common in patients with CNSD 
(21.9%) than those with IBS (8.5%) and healthy controls (2%). 
Since CNSD including diarrhea predominant IBS (D-IBS) had 
higher frequency of SIBO, the authors suggested clinicians to 
consider testing for SIBO among them. However, since false 
positive GHBT could result from rapid intestinal transit in pa-
tients with diarrhea, the frequency of SIBO in patients with 
CNSD and D-IBS demonstrated in the author’s study might 
have been overestimated in part.
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